Continuous cyclophosphamide, doxorubicin, vincristine, and prednisolone. A new, innovative protocol for diffuse aggressive lymphomas
Journal Article
·
· Cancer (Philadelphia); (USA)
DOI:https://doi.org/10.1002/1097-0142(19900415)65:8<1704::AID-CNCR2820650807>3.0.CO;2-R·
OSTI ID:6946033
- Tata Memorial Hospital, Bombay (India)
One hundred eight patients with aggressive non-Hodgkin's lymphoma (high and intermediate grade) were treated with a new protocol: continuous cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). They were evaluated for long-term survival and pretreatment characteristics predictive of response and survival. Continuous CHOP protocol consists of initial 8 weeks of intensive chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone, followed by local/cranial radiotherapy and maintenance therapy. Complete remission (CR) was achieved in 84 of 108 (78%) patients; seven (6%) had a moderate response and 17 (16%) had a poor response. A statistically significant difference in CR rate was found only in patients with different stages. Seventeen of 84 (20%) complete responders have had a relapse of the disease. The median survival has not been reached. Results show an actuarial disease-free survival (DFS) of 77% for the 84 patients who had a complete response. The overall survival for all patients was 53% at 5 years of follow-up. The difference in DFS at the end of 5 years between different stages, main histologic subgroups, and age groups was not statistically significant. The toxicity observed was acceptable. Thus continuous CHOP appears to be an effective protocol for the treatment of intermediate-grade and high-grade lymphomas.
- OSTI ID:
- 6946033
- Journal Information:
- Cancer (Philadelphia); (USA), Journal Name: Cancer (Philadelphia); (USA) Vol. 65:8; ISSN 0008-543X; ISSN CANCA
- Country of Publication:
- United States
- Language:
- English
Similar Records
A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin's lymphoma
Primary Mediastinal Large B-Cell Lymphoma: Results of Intensive Chemotherapy Regimens (MACOP-B/VACOP-B) Plus Involved Field Radiotherapy on 53 Patients. A Single Institution Experience
Combination chemotherapy of lymphomas other than Hodgkin's disease. [Vincristine, prednisone, cyclophosphamide, procarbazine]
Journal Article
·
Fri Sep 01 00:00:00 EDT 2006
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:20850073
Primary Mediastinal Large B-Cell Lymphoma: Results of Intensive Chemotherapy Regimens (MACOP-B/VACOP-B) Plus Involved Field Radiotherapy on 53 Patients. A Single Institution Experience
Journal Article
·
Sun Jul 01 00:00:00 EDT 2007
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:20951711
Combination chemotherapy of lymphomas other than Hodgkin's disease. [Vincristine, prednisone, cyclophosphamide, procarbazine]
Journal Article
·
Thu Oct 31 23:00:00 EST 1974
· Ann. Intern. Med.; (United States)
·
OSTI ID:5276418
Related Subjects
550600 -- Medicine
550603* -- Medicine-- External Radiation in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ADRENAL HORMONES
ANTI-INFECTIVE AGENTS
ANTIBIOTICS
ANTINEOPLASTIC DRUGS
COMBINED THERAPY
CORTICOSTEROIDS
DISEASES
DOXORUBICIN
DRUGS
GLUCOCORTICOIDS
HYDROXY COMPOUNDS
IMMUNE SYSTEM DISEASES
KETONES
LYMPHOMAS
NEOPLASMS
ORGANIC COMPOUNDS
PATIENTS
PREDNISOLONE
PREGNANES
STEROIDS
SURVIVAL CURVES
THERAPY
550603* -- Medicine-- External Radiation in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ADRENAL HORMONES
ANTI-INFECTIVE AGENTS
ANTIBIOTICS
ANTINEOPLASTIC DRUGS
COMBINED THERAPY
CORTICOSTEROIDS
DISEASES
DOXORUBICIN
DRUGS
GLUCOCORTICOIDS
HYDROXY COMPOUNDS
IMMUNE SYSTEM DISEASES
KETONES
LYMPHOMAS
NEOPLASMS
ORGANIC COMPOUNDS
PATIENTS
PREDNISOLONE
PREGNANES
STEROIDS
SURVIVAL CURVES
THERAPY